US Edition
Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Report
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Report
Nordic Pharma, a subsidiary of Nordic Group BV, announced that its Lacrifill Canalicular Gel—a novel therapy for the relief of dry eye symptoms—has been featured in the newly released Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS). The TFOS DEWS III report, published in the June 2025 issue of the American Journal of Ophthalmology, cites two clinical studies evaluating Nordic Pharma’s crosslinked hyaluron…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
